In healthcare, we have traditionally operated in silos. Patient Support Programs (PSPs) focus on improving patient adherence, while clinical research separately focuses on generating evidence of efficacy. But what if we could merge these two worlds? What if the very act of supporting patients could simultaneously generate the crucial data needed to prove the economic value of their therapy?

This is the power of pairing Real-World Evidence (RWE) generation with a PSP. It creates a dynamic feedback loop that benefits everyone: patients, providers, and most critically, the payers and health systems making difficult funding decisions.

A well-designed, digitally-enabled PSP is a goldmine of Real-World Data (RWD). As patients engage with the program, they provide information that goes far beyond simple adherence metrics. We can collect patient-reported outcomes (PROs), track quality of life changes, and understand the daily challenges patients face—all in a natural, real-world setting. This data is far more reflective of a typical patient’s journey than data from a controlled clinical trial.

When we analyze this RWD to create RWE, we can use that evidence to improve the PSP itself in near real-time. But the greatest impact lies in its application to health economics.

In Canada, Health Technology Assessment (HTA) bodies like CADTH evaluate new drugs not just on their clinical effectiveness, but on their cost-effectiveness. They ask: “Does the benefit of this new, often expensive, drug justify its cost to the healthcare system?” This is where RWE from a PSP becomes a game-changer. It can provide concrete answers by demonstrating:

• Reduced Healthcare Utilization: Does the drug, when paired with a support program, lead to fewer emergency room visits, shorter hospital stays, or a reduced need for other medications? This RWE provides direct inputs for cost-effectiveness models.
• Improved Productivity: Can we show that patients on this therapy miss fewer days of work or are more productive? This demonstrates a broader societal economic benefit.
• Long-Term Value: RWE from a PSP allows us to track a therapy’s impact over years, not just the few months of a clinical trial, proving its long-term value and justifying investment.

Pairing RWE with PSPs transforms a support program from a cost center into a powerful evidence-generation engine for health economic decisions. It allows us to speak the language of value that payers and health systems understand, ensuring that innovative and effective treatments can get into the hands of the patients who need them most.